Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiology Reports
Erschienen in: Current Cardiology Reports 8/2016

01.08.2016 | Management of Acute Coronary Syndromes (AS Jaffe, Section Editor)

Revascularization Strategies in Patients with Diabetes Mellitus and Acute Coronary Syndrome

verfasst von: Adam J. Buntaine, Binita Shah, Jeffrey D. Lorin, Steven P. Sedlis

Erschienen in: Current Cardiology Reports | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

Patients with diabetes mellitus (DM) have more severe CAD and higher mortality in acute coronary syndrome (ACS) than patients without DM. The optimal mode of revascularization—coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)—remains controversial in this setting. For patients with DM and ST-segment elevation myocardial infarction, prompt revascularization of the culprit artery via PCI is generally preferable. In non-ST-elevation ACS, the decision on mode of revascularization is more challenging. Trials comparing CABG with percutaneous transluminal coronary angioplasty, bare metal stents, and first-generation drug-eluting stents in DM patients with multivessel have demonstrated decreased mortality in those receiving CABG. On the other hand, trials and retrospective analyses comparing CABG to PCI with second-generation drug-eluting stents have not shown a statistically significant mortality benefit favoring CABG. This potentially narrowed that gap between CABG and PCI requires further investigation.
Literatur
1.
The Bypass Angioplasty Revascularization Investigation (BARI) Investigators. Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. N Engl J Med. 1996;335(4):217–25.CrossRef
2.••
Farkouh ME, Domanski M, Sleeper LA, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012;367(25):2375–84. The FREEDOM study is a landmark randomized trial in patients with DM and multivessel CAD, which showed mortality benefit at long-term follow-up favoring CABG over PCI with 1st-generation drug-eluting stents.CrossRefPubMed
3.
Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients. 1-year results of the CARDia (coronary artery revascularization in diabetes) trial. J Am Coll Cardiol. 2010;55(5):432–40.CrossRefPubMed
4.
Serruys PW, Morice MC, Kappetein AP, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009;360(10):961–72.CrossRefPubMed
5.•
Ben-Gal Y, Mohr R, Feit F, et al. Surgical versus percutaneous coronary revascularization for multivessel disease in diabetic patients with non-ST-segment-elevation acute coronary syndrome: analysis from the acute catheterization and early intervention triage strategy trial. Circ Cardiovasc Interv, 2015. 8(6). This is an analysis of the patients with DM previously enrolled in the ACUITY trial with ACS. After propensity matching CABG and PCI groups, there was no statistically significant difference in mortality at 1-year follow-up.
6.••
Bangalore S, Guo Y, Samadashvili Z, et al. Everolimus eluting stents versus coronary artery bypass graft surgery for patients with diabetes mellitus and multivessel disease. Circ Cardiovasc Interv. 2015;8(7):e002626. This is a retrospective analysis of patients drawn from NY State registries who underwent either CABG or PCI with 2nd generation drug eluting stents. After propensity matching of the groups, the authors found no statistically significant difference in 5-year mortality between the groups.CrossRefPubMed
7.
Grundy SM, Benjamin IJ, Burke GL, et al. Diabetes and cardiovascular disease: a statement for healthcare professionals from the american heart association. Circulation. 1999;100(10):1134–46.CrossRefPubMed
8.
National diabetes statistics report, 2014. 2014.
9.
Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339(4):229–34.CrossRefPubMed
10.
Malmberg K, Yusuf S, Gerstein HC, et al. Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (organization to assess strategies for ischemic syndromes) registry. Circulation. 2000;102(9):1014–9.CrossRefPubMed
11.
Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med. 2000;342(3):145–53.CrossRefPubMed
12.
National Cholesterol Education Program Expert Panel on Detection E and Treatment of High Blood Cholesterol in A. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106(25):3143–421.
13.
Emerging Risk Factors C, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215–22.CrossRef
14.
Waller BF, Palumbo PJ, Lie JT, et al. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med. 1980;69(4):498–506.CrossRefPubMed
15.
Pajunen P, Taskinen MR, Nieminen MS, et al. Angiographic severity and extent of coronary artery disease in patients with type 1 diabetes mellitus. Am J Cardiol. 2000;86(10):1080–5.CrossRefPubMed
16.
Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous transluminal coronary angioplasty. Circulation. 1995;91(4):979–89.CrossRefPubMed
17.
Granger CB, Califf RM, Young S, et al. Outcome of patients with diabetes mellitus and acute myocardial infarction treated with thrombolytic agents. The thrombolysis and angioplasty in myocardial infarction (TAMI) study group. J Am Coll Cardiol. 1993;21(4):920–5.CrossRefPubMed
18.
Mueller HS, Cohen LS, Braunwald E, et al. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the thrombolysis in myocardial infarction (TIMI) trial, phase II. Circulation. 1992;85(4):1254–64.CrossRefPubMed
19.
Natali A, Vichi S, Landi P, et al. Coronary atherosclerosis in type II diabetes: angiographic findings and clinical outcome. Diabetologia. 2000;43(5):632–41.CrossRefPubMed
20.
Robertson WB, Strong JP. Atherosclerosis in persons with hypertension and diabetes mellitus. Lab Investig. 1968;18(5):538–51.PubMed
21.
Nicholls SJ, Tuzcu EM, Crowe T, et al. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol. 2006;47(10):1967–75.CrossRefPubMed
22.
Uddin SN, Malik F, Bari MA, et al. Angiographic severity and extent of coronary artery disease in patients with type 2 diabetes mellitus. Mymensingh Med J. 2005;14(1):32–7.PubMed
23.
Scognamiglio R, Negut C, Ramondo A, et al. Detection of coronary artery disease in asymptomatic patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2006;47(1):65–71.CrossRefPubMed
24.
Piga R, Naito Y, Kokura S, et al. Short-term high glucose exposure induces monocyte-endothelial cells adhesion and transmigration by increasing VCAM-1 and MCP-1 expression in human aortic endothelial cells. Atherosclerosis. 2007;193(2):328–34.CrossRefPubMed
25.
Otsuka A, Azuma K, Iesaki T, et al. Temporary hyperglycaemia provokes monocyte adhesion to endothelial cells in rat thoracic aorta. Diabetologia. 2005;48(12):2667–74.CrossRefPubMed
26.
Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and E-selectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis. 2005;183(2):259–67.CrossRefPubMed
27.
Kilhovd BK, Berg TJ, Birkeland KI, et al. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care. 1999;22(9):1543–8.CrossRefPubMed
28.
Guzzardi MA, Hodson L, Guiducci L, et al. Independent effects of circulating glucose, insulin and NEFA on cardiac triacylglycerol accumulation and myocardial insulin resistance in a swine model. Diabetologia. 2014;57(9):1937–46.CrossRefPubMed
29.
Shoelson SE, Lee J, Yuan M. Inflammation and the IKK beta/I kappa B/NF-kappa B axis in obesity- and diet-induced insulin resistance. Int J Obes Relat Metab Disord. 2003;27(3):S49–52.CrossRefPubMed
30.
Shah B, Sha D, Xie D, et al. The relationship between diabetes, metabolic syndrome, and platelet activity as measured by mean platelet volume: the national health and nutrition examination survey, 1999–2004. Diabetes Care. 2012;35(5):1074–8.CrossRefPubMedPubMedCentral
31.
Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24(8):1476–85.CrossRefPubMed
32.
Cortigiani L, Rigo F, Gherardi S, et al. Prognostic meaning of coronary microvascular disease in type 2 diabetes mellitus: a transthoracic doppler echocardiographic study. J Am Soc Echocardiogr. 2014;27(7):742–8.CrossRefPubMed
33.
Kiviniemi AM, Hautala AJ, Karjalainen JJ, et al. Impact of type 2 diabetes on cardiac autonomic responses to sympathetic stimuli in patients with coronary artery disease. Auton Neurosci. 2013;179(1–2):142–7.CrossRefPubMed
34.
Su X, Han X, Mancuso DJ, et al. Accumulation of long-chain acylcarnitine and 3-hydroxy acylcarnitine molecular species in diabetic myocardium: identification of alterations in mitochondrial fatty acid processing in diabetic myocardium by shotgun lipidomics. Biochemistry. 2005;44(13):5234–45.CrossRefPubMed
35.
Harris IS, Treskov I, Rowley MW, et al. G-protein signaling participates in the development of diabetic cardiomyopathy. Diabetes. 2004;53(12):3082–90.CrossRefPubMed
36.
Vaccarino V, Parsons L, Every NR, et al. Impact of history of diabetes mellitus on hospital mortality in men and women with first acute myocardial infarction. The national registry of myocardial infarction 2 participants. Am J Cardiol. 2000;85(12):1486–9. A7.CrossRefPubMed
37.
Ulvenstam G, Aberg A, Bergstrand R, et al. Long-term prognosis after myocardial infarction in men with diabetes. Diabetes. 1985;34(8):787–92.CrossRefPubMed
38.
Miettinen H, Lehto S, Salomaa V, et al. Impact of diabetes on mortality after the first myocardial infarction. The FINMONICA myocardial infarction register study group. Diabetes Care. 1998;21(1):69–75.CrossRefPubMed
39.
Donahue RP, Goldberg RJ, Chen Z, et al. The influence of sex and diabetes mellitus on survival following acute myocardial infarction: a community-wide perspective. J Clin Epidemiol. 1993;46(3):245–52.CrossRefPubMed
40.
Chun BY, Dobson AJ, Heller RF. The impact of diabetes on survival among patients with first myocardial infarction. Diabetes Care. 1997;20(5):704–8.CrossRefPubMed
41.
Behar S, Boyko V, Reicher-Reiss H, et al. Ten-year survival after acute myocardial infarction: comparison of patients with and without diabetes. SPRINT study group. Secondary prevention reinfarction Israeli nifedipine trial. Am Heart J. 1997;133(3):290–6.CrossRefPubMed
42.
Abbott RD, Donahue RP, Kannel WB, et al. The impact of diabetes on survival following myocardial infarction in men vs women. The Framingham study. JAMA. 1988;260(23):3456–60.CrossRefPubMed
43.
Banks AD, Dracup K. Factors associated with prolonged prehospital delay of African americans with acute myocardial infarction. Am J Crit Care. 2006;15(2):149–57.PubMed
44.
Sari I, Acar Z, Ozer O, et al. Factors associated with prolonged prehospital delay in patients with acute myocardial infarction. Turk Kardiyol Dern Ars. 2008;36(3):156–62.PubMed
45.
Jaffe AS, Spadaro JJ, Schechtman K, et al. Increased congestive heart failure after myocardial infarction of modest extent in patients with diabetes mellitus. Am Heart J. 1984;108(1):31–7.CrossRefPubMed
46.
Stone PH, Muller JE, Hartwell T, et al. The effect of diabetes mellitus on prognosis and serial left ventricular function after acute myocardial infarction: contribution of both coronary disease and diastolic left ventricular dysfunction to the adverse prognosis. The MILIS study group. J Am Coll Cardiol. 1989;14(1):49–57.CrossRefPubMed
47.
Melchior T, Rask-Madsen C, Torp-Pedersen C, et al. The impact of heart failure on prognosis of diabetic and non-diabetic patients with myocardial infarction: a 15-year follow-up study. Eur J Heart Fail. 2001;3(1):83–90.CrossRefPubMed
48.
The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329(10):673–82.CrossRef
49.
Mak KH, Moliterno DJ, Granger CB, et al. Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I investigators. Global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries. J Am Coll Cardiol. 1997;30(1):171–9.CrossRefPubMed
50.
Jensen LO, Thayssen P, Junker A, et al. Comparison of outcomes in patients with versus without diabetes mellitus after revascularization with everolimus- and sirolimus-eluting stents (from the SORT OUT IV trial). Am J Cardiol. 2012;110(11):1585–91.CrossRefPubMed
51.
Calvin JE, Klein LW, VandenBerg BJ, et al. Risk stratification in unstable angina. Prospective validation of the braunwald classification. JAMA. 1995;273(2):136–41.CrossRefPubMed
52.
Fava S, Azzopardi J, Agius-Muscat H. Outcome of unstable angina in patients with diabetes mellitus. Diabet Med. 1997;14(3):209–13.CrossRefPubMed
53.
Muller C, Neumann FJ, Ferenc M, et al. Impact of diabetes mellitus on long-term outcome after unstable angina and non-ST-segment elevation myocardial infarction treated with a very early invasive strategy. Diabetologia. 2004;47(7):1188–95.CrossRefPubMed
54.
Boden WE, O’Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007;356(15):1503–16.CrossRefPubMed
55.
Group BDS, Frye RL, August P, et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360(24):2503–15.CrossRef
56.
Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with Non-ST-elevation acute coronary syndromes: a report of the american college of cardiology/american heart association task force on practice guidelines. J Am Coll Cardiol. 2014;64(24):e139–228.CrossRefPubMed
57.
O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the american college of cardiology foundation/american heart association task force on practice guidelines. J Am Coll Cardiol. 2013;61(4):e78–140.CrossRefPubMed
58.
Hochman JS, Sleeper LA, Webb JG, et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med. 1999;341(9):625–34.CrossRefPubMed
59.
Farkouh ME, Ramanathan K, Aymong ED, et al. An early revascularization strategy is associated with a survival benefit for diabetic patients in cardiogenic shock after acute myocardial infarction. Clin Cardiol. 2006;29(5):204–10.CrossRefPubMed
60.
Shindler DM, Palmeri ST, Antonelli TA, et al. Diabetes mellitus in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK trial registry. Should we emergently revascularize occluded coronaries for cardiogenic shocK? J Am Coll Cardiol. 2000;36(3 Suppl A):1097–103.CrossRefPubMed
61.
Figueras J, Cortadellas J, Calvo F, et al. Relevance of delayed hospital admission on development of cardiac rupture during acute myocardial infarction: study in 225 patients with free wall, septal or papillary muscle rupture. J Am Coll Cardiol. 1998;32(1):135–9.CrossRefPubMed
62.
Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2016;67(10):1235–50.CrossRefPubMed
63.
Wald DS, Morris JK, Wald NJ, et al. Randomized trial of preventive angioplasty in myocardial infarction. N Engl J Med. 2013;369(12):1115–23.CrossRefPubMed
64.
Gershlick AH, Khan JN, Kelly DJ, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015;65(10):963–72.CrossRefPubMedPubMedCentral
65.
Engstrom T, Kelbaek H, Helqvist S, et al. Complete revascularisation versus treatment of the culprit lesion only in patients with ST-segment elevation myocardial infarction and multivessel disease (DANAMI-3-PRIMULTI): an open-label, randomised controlled trial. Lancet. 2015;386(9994):665–71.CrossRefPubMed
66.
Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the arterial revascularization therapies study (ARTS) randomized trial. J Am Coll Cardiol. 2005;46(4):575–81.CrossRefPubMed
67.
Investigators B. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007;49(15):1600–6.CrossRef
68.
Participants CT. First-year results of CABRI (coronary angioplasty versus bypass revascularisation investigation). CABRI trial participants. Lancet. 1995;346(8984):1179–84.CrossRef
69.
King 3rd SB, Kosinski AS, Guyton RA, et al. Eight-year mortality in the Emory angioplasty versus surgery trial (EAST). J Am Coll Cardiol. 2000;35(5):1116–21.CrossRefPubMed
70.
Rodriguez AE, Baldi J, Fernandez Pereira C, et al. Five-year follow-up of the argentine randomized trial of coronary angioplasty with stenting versus coronary bypass surgery in patients with multiple vessel disease (ERACI II). J Am Coll Cardiol. 2005;46(4):582–8.CrossRefPubMed
71.
Kaehler J, Koester R, Billmann W, et al. 13-year follow-up of the German angioplasty bypass surgery investigation. Eur Heart J. 2005;26(20):2148–53.CrossRefPubMed
72.
Hueb W, Lopes NH, Gersh BJ, et al. Five-year follow-up of the medicine, angioplasty, or surgery study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2007;115(9):1082–9.CrossRefPubMed
73.
Henderson RA, Pocock SJ, Sharp SJ, et al. Long-term results of RITA-1 trial: clinical and cost comparisons of coronary angioplasty and coronary-artery bypass grafting. Randomised intervention treatment of angina. Lancet. 1998;352(9138):1419–25.CrossRefPubMed
74.
Booth J, Clayton T, Pepper J, et al. Randomized, controlled trial of coronary artery bypass surgery versus percutaneous coronary intervention in patients with multivessel coronary artery disease: six-year follow-up from the stent or surgery trial (SoS). Circulation. 2008;118(4):381–8.CrossRefPubMed
75.
Carrie D, Elbaz M, Puel J, et al. Five-year outcome after coronary angioplasty versus bypass surgery in multivessel coronary artery disease: results from the french monocentric study. Circulation. 1997;96(9):II-1-6.PubMed
76.
Hlatky MA, Boothroyd DB, Bravata DM, et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet. 2009;373(9670):1190–7.CrossRefPubMed
77.
Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012;379(9824):1393–402.CrossRefPubMed
78.
Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–15.CrossRefPubMed
79.
Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045–57.CrossRefPubMed
80.••
Head SJ, Davierwala PM, Serruys PW, et al. Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. Eur Heart J. 2014;35(40):2821–30. This study presents the 5-year data from the SYNTAX trial, in which patients with multivessel CAD were randomized to either CABG or PCI with 1st-generation drug-eluting stents. They demonstrate a statistically significant mortality benefit favoring CABG over PCI. In those with CAD of low complexity, there was no statistically significant difference in mortality between the groups.CrossRefPubMed
81.•
Kurlansky P, Herbert M, Prince S, et al. Improved long-term survival for diabetic patients with surgical versus interventional revascularization. Ann Thorac Surg. 2015;99(4):1298–305. This is an all-comers retrospective analysis comparing patients who underwent CABG or PCI with 1st generation DES at 8 community hospitals, designed to confirm the results of the FREEDOM and SYNTAX trials. Indeed, in this more inclusive sample, they demonstrated a statistically signifincat lower mortality rate in the CABG-treated patients compared to the PCI-treated patients.CrossRefPubMed
82.•
Park SJ, Ahn JM, Kim YH, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med. 2015;372(13):1204–12. This is a randomized trial designed to compare CABG vs. PCI with 2nd- generation DES in patients with multivessel disease. Due to slow enrollment, it was stopped early.CrossRefPubMed
83.
Bangalore S, Guo Y, Samadashvili Z, et al. Everolimus-eluting stents or bypass surgery for multivessel coronary disease. N Engl J Med. 2015;372(13):1213–22.CrossRefPubMed
84.
Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the american college of cardiology foundation/american heart association task force on practice guidelines, and the american college of physicians, american association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. J Am Coll Cardiol. 2012;60(24):e44–e164.CrossRefPubMed
85.
Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the american college of cardiology/american heart association task force on practice guidelines, and the american association for thoracic surgery, preventive cardiovascular nurses association, society for cardiovascular angiography and interventions, and society of thoracic surgeons. Circulation. 2014;130(19):1749–67.CrossRefPubMed
86.
Authors/Task Force m, Windecker S, Kolh P, et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the european society of cardiology (ESC) and the european association for cardio-thoracic surgery (EACTS)developed with the special contribution of the european association of percutaneous cardiovascular interventions (EAPCI). Eur Heart J. 2014;35(37):2541–619.CrossRef
Metadaten
Titel
Revascularization Strategies in Patients with Diabetes Mellitus and Acute Coronary Syndrome
verfasst von
Adam J. Buntaine
Binita Shah
Jeffrey D. Lorin
Steven P. Sedlis
Publikationsdatum
01.08.2016
Verlag
Springer US
Erschienen in
Current Cardiology Reports / Ausgabe 8/2016
Print ISSN: 1523-3782
Elektronische ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-016-0756-3

Weitere Artikel der Ausgabe 8/2016

Current Cardiology Reports 8/2016 Zur Ausgabe

New Therapies for Cardiovascular Disease (KW Mahaffey, Section Editor)

The ADAPTABLE Trial and Aspirin Dosing in Secondary Prevention for Patients with Coronary Artery Disease

Cardiovascular Genomics (TL Assimes, Section Editor)

Genetics of Insulin Resistance and the Metabolic Syndrome

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

His Bundle Pacing: Techniques and Outcomes

Myocardial Disease (M Patel, Section Editor)

Hypertrophic Cardiomyopathy: New Evidence Since the 2011 American Cardiology of Cardiology Foundation and American Heart Association Guideline

Cardiac PET, CT, and MRI (SE Petersen and F Pugliese, Section Editors)

Aortic Stenosis, a Left Ventricular Disease: Insights from Advanced Imaging

Invasive Electrophysiology and Pacing (EK Heist, Section Editor)

Use of the Wearable Cardioverter Defibrillator in High-Risk Populations

Neu im Fachgebiet Kardiologie

16.04.2024 | Chronische Herzinsuffizienz | Nachrichten

Sind Betablocker auch für ältere herzschwache Personen nützlich?

16.04.2024 | Stillen, Säuglingsnahrung, Beikost | Nachrichten

Stillende Frauen haben geringeres kardiovaskuläres Risiko

15.04.2024 | ACC 2024 | Kongressbericht | Nachrichten

Selbstexpandierende TAVI-Klappen bei kleinem Aortenanulus im Vorteil

15.04.2024 | ACC 2024 | Kongressbericht | Nachrichten

Verbesserung der HDL-Funktion als Lipidtherapie floppt in Mega-Studie
weitere anzeigen

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen